The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.
 
Philipp Harter
Honoraria - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Lilly; MSD Oncology; Roche; Sotio; Stryker; Zai Lab
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Immunogen; Merck; Roche; Tesaro
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Roche (Inst)
 
Fabian Trillsch
Honoraria - AstraZeneca; Clovis Oncology; Eisai; MSD Oncology; Roche; Tesaro/GSK
Consulting or Advisory Role - AstraZeneca; Eisai Germany; Immunogen; MSD Oncology; Roche; Tesaro/GSK
Research Funding - AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Immunogen; Tesaro/GSK
 
Aikou Okamoto
Honoraria - AstraZeneca Japan; Chugai Pharma; Eisai; Kaken Pharmaceutical; MSD; Takeda; Zeria Pharmaceutical
Speakers' Bureau - AstraZeneca Japan
Research Funding - ASKA Pharmaceutical Co., Ltd. (Inst); AstraZeneca Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo Co., Ltd. (Inst); Eisai (Inst); Fuji Pharma (Inst); Gyne Mom Co. (Inst); Kaken Pharmaceutical (Inst); Kissei Pharmaceutical (Inst); Linical (Inst); Meiji holdings (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD K.K. (Inst); Nippon Shinyaku (Inst); Pfizer (Inst); Shinnihonseiyaku (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TERUMO (Inst); Tsumura & Co. (Inst)
 
Alexander Reuss
No Relationships to Disclose
 
Jae-Weon Kim
No Relationships to Disclose
 
Maria Jesús Rubio-Pérez
No Relationships to Disclose
 
Mehmet Ali Vardar
No Relationships to Disclose
 
Giovanni Scambia
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; PharmaMar; Roche; Tesaro
Speakers' Bureau - Clovis Oncology; MSD
 
Olivier Tredan
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Eisai Europe; Gilead Sciences; Lilly; MSD Oncology; Pfizer; Pierre Fabre; Roche; Sandoz-Novartis; Seagen; Stemline Therapeutics; Viatris
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; MSD Oncology; Novartis; Pfizer; Roche
 
Gitte-Bettina Nyvang
No Relationships to Disclose
 
Nicoletta Colombo
Employment - Sarepta Therapeutics (I)
Honoraria - Advaxis; Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novartis; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech
Consulting or Advisory Role - Advaxis; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech
 
Anita M. Chudecka-Głaz
Honoraria - Aravive; AstraZeneca; GlaxoSmithKline; Novocure
Consulting or Advisory Role - GlaxoSmithKline
 
Christoph Grimm
Consulting or Advisory Role - AstraZeneca; Eisai Europe; GlaxoSmithKline; MSD Oncology
Speakers' Bureau - AstraZeneca; Eisai Europe; GlaxoSmithKline; Merck
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; GlaxoSmithKline
 
Stephanie Lheureux
Honoraria - AstraZeneca; GlaxoSmithKline; Merck; Roche/Genentech; Shattuck Labs
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Merck; Novartis; Roche/Genentech; Shattuck Labs
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Roche/Genentech (Inst); Tesaro (Inst)
 
Els Van Nieuwenhuysen
Consulting or Advisory Role - Regeneron (Inst)
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Seagen (Inst)
 
Florian Heitz
Honoraria - AstraZeneca; Roche; Tesaro/GSK
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Novocure; PharmaMar; Roche
Research Funding - Amedes (Inst); AstraZeneca (Inst)
 
Robert M. Wenham
Stock and Other Ownership Interests - Ovation Diagnostics
Honoraria - Seagen; Tesaro
Consulting or Advisory Role - Abbvie; AstraZeneca; Clovis Oncology; Eisai; Genentech; GlaxoSmithKline; Immunogen; Legend Biotech; Merck; Mersana; Regeneron; Seattle Genetics/Astellas; Sonnet; Sonnet; Tesaro
Speakers' Bureau - Clovis Oncology; Genentech; Tesaro
Research Funding - Anixa Biosciences (Inst); Merck (Inst); Prescient Therapeutics (Inst)
Travel, Accommodations, Expenses - Eisai
Other Relationship - AstraZeneca; GlaxoSmithKline/Tesaro
 
Kimio Ushijima
Honoraria - AstraZeneca; Asuka Seiyaku; Chugai Pharma; Kaken Pharmaceutical; Kyowa Kirin International; Mochida Pharmaceutical Co. Ltd.; MSD; Sanofi; Takeda; Zeria Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Emily Day
Employment - AstraZeneca; Exploristics
Research Funding - Imperial College London
 
Carol Aghajanian
Consulting or Advisory Role - AstraZeneca/Merck; Eisai; Repare Therapeutics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst)